Cognitive Claims Stir Senators To Question FDA Supplement Regulation
This article was originally published in The Tan Sheet
Executive Summary
Senator McCaskill says FDA might “lack a systematic approach to preventing adulterated, mislabeled and fraudulent products from entering the market.” She and Senator Susan Collins ask FDA for a “detailed description” of the agency’s evaluation of medical and nutritional claims for supplements on the market.”
You may also be interested in...
McCaskill Not Sold On Retailer Exemption From Supplement AER Filing
FDA regulations exempt retailers from compiling supplement adverse event reports, even for products that bear a store brand. Private label firms or contract manufacturers are required to receive AERs linked to those products and to forward reports of serious events to FDA within 15 days.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
US Health And Wellness People News: CHPA, Bayer, Viatris, Qnovia, Powerade
Sanofi consumer health scientific affairs lead moves to CHPA; change in Bayer’s US consumer health marketing helm; Viatris CCO moves from same post at Moderna; Qnovia expands scientific advisory board; and Powerade powers Girls Inc. scholarships, programs.